| Over a week ago | ||||
Quotient Limited… Quotient Limited announced that the Company has been added to the Russell 2000 and 3000 Indexes, effective June 29, 2020 as part of the 2020 Russell U.S. indexes reconstitution. | ||||
| Over a month ago | ||||
A forecast of COVID-19… A forecast of COVID-19 antibody tests is not currently possible due to the uncertainties related to the development of this new market. No other revenues are expected. Sees FY20 Capital expenditures $5M-$10M; average monthly cash use for operations $5M-$6M excluding potential revenue related to COVID-19 antibody test. Sees Q1 Alba by Quotient product sales of $8.4M-$8.9M, compared with $8.2M for the Q1 of FY20. The company stated, "The Company is not providing guidance on the operating loss due to the uncertainty around revenues derived from MosaiQ by Quotient COVID-19 antibody tests. Quarterly product sales can fluctuate depending upon the shipment cycles for red blood cell-based products, which account for approximately two-thirds of current product sales. These products typically experience 13 shipment cycles per year, equating to three shipments of each product per quarter, except for one quarter per year when four shipments occur. The timing of shipment of bulk antisera products to OEM customers may also move revenues from quarter to quarter. Some seasonality in demand is also experienced around holiday periods in both Europe and the United States. As a result of these factors, Quotient expects to continue to see seasonality and quarter-to-quarter variations in product sales. The timing of product development fees included in other revenues is mostly dependent upon the achievement of pre-negotiated project milestones." | ||||
Reports Q4 revenue $8.7M,… Reports Q4 revenue $8.7M, consensus $7.93M. "The global coronavirus crisis was a shock to everyone, but we are very proud of how the Quotient team leveraged the knowledge we acquired over the past eight years, and the flexibility of the MosaiQ platform, to develop a state of the art COVID-19 antibody test. The test performs with 100% sensitivity and 99.8% specificity and detects antibodies early due to its sensitivity to both IgM and IgG antibodies. The fact that we were able to sign several MosaiQ COVID-19 antibody test customer contracts, demonstrates the attractiveness of our innovative MosaiQ platform," said Franz Walt, CEO of Quotient. | ||||
Cowen analyst Joshua… Cowen analyst Joshua Jennings made no change to his Outperform rating and $14 price target on Quotient shares after Open Orphan issued a statement indicating that MosaiQ is on site at its lab and is set to be fully operational within to weeks. Jennings tells investors in a research note that he continues to be encouraged by Quotient's progress in the EU for its antibody test and awaits receipt of an EUA from the FDA, which he expects "imminently." | ||||
Open Orphan plc noted an… Open Orphan plc noted an increase in the company's share price and media comment regarding its collaboration with Quotient Limited. Furthermore, it also notes the substantial increase in interest in antibody testing for Covid-19 following recent announcements by the UK Government. "The company confirms that the MosaiQ COVID-19 Antibody Microarray machine is on site at hVivo's laboratory in East London and is undergoing testing. It is expected to be fully operational within two weeks following which it will have capability to undertake up to 3,000 tests a day, in line with expected performance as stated by Quotient Limited. The company intends to enter into discussions with channel partners to secure testing volumes with pricing to be determined as part of these negotiations. It is not the company's intention to deal directly with consumers and while there can be no certainty on pricing until such time as terms are agreed, the company notes current market prices ranging from c.GBP 70 for home testing kits and upwards towards c.GBP 150. It is the intention to supply testing capability to channel partners, who will in turn deal with the end users and the final price points. The company will update shareholders in due course," Open Orphan stated. Reference Link | ||||
Quotient and hVIVO, part… Quotient and hVIVO, part of Open Orphan, announced that the MosaiQ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO's exclusive supplier of COVID-19 antibody testing equipment, to support COVID-19 antibody testing in the UK. hVIVO, based in London, UK, is a world leader in the testing of vaccines and antivirals using human challenge study models. | |
Quotient Limited… Quotient Limited announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro Diagnostics Directive and has CE marked its SARS-CoV-2 antibody microarray. The test is now available for sale in Europe and Switzerland. The MosaiQ COVID-19 Antibody Microarray is designed as a serological disease screen specific to COVID-19. The assay detects the IgG and IgM antibodies directed at SARS-CoV-2. In addition to the concordance studies, the Company observed seroconversions in two patients where diagnosis was supported by a polymerase chain reaction assay on the patients at the time of symptoms. In one patient, the antibody negative status changed to positive one day after the PCR positive result, and in another patient, the antibody negative status changed to positive four days post PCR result. This demonstrates that the MosaiQ antibody test can detect antibodies very early in seroconversion process. This the Company's fourth market clearance and the CE certification of the third Microarray within a year. The MosaiQ instrument is CE marked and the Company's microarray manufacturing facility is ISO 13485 certified. | |
Check out this morning's… | |
Check out this evening's… | |